ArticleMarine biotechnology (New York, N.Y.)2026
Purification, Identification, and Functional Validation of Anti-Inflammatory Peptides from Protein Hydrolysates of Asian Seabass, Lates Calcarifer by-Product.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fish processing by-products are increasingly recognized as sustainable raw materials for generating bioactive protein hydrolysates. In the present study, hydrolysates derived from Asian seabass (Lates calcarifer) by-products were produced and their anti-inflammatory potential was investigated in lipopolysaccharide (LPS)-activated RAW264.7 macrophages. The results showed that the hydrolysates were non-cytotoxic at concentrations up to 0.5 mg/mL and significantly reduced nitric oxide (NO) production. Fractionation by ultrafiltration indicated that the 10–30 kDa fraction possessed the greatest inhibitory effect on NO release. Further purification using gel filtration chromatography concentrated the activity in Fraction F2, which effectively suppressed NO generation, decreased the expression of pro-inflammatory cytokines (TNF-α, IL6, and IL1β), and regulated anti-inflammatory mediators. Peptide identification by LC–MS/MS combined with in silico prediction (PreAIP) yielded five peptides with high anti-inflammatory potential. Molecular docking with the TLR4/MD-2 complex (PDB: 2Z64) revealed that two peptides, LALDIEIATYR (LR-11) and LKLLLL (LL-6), exhibited favorable and stable binding interactions. Synthetic peptide assays further confirmed that both LR-11 and LL-6 significantly attenuated LPS-induced inflammatory responses, with LR-11 demonstrating stronger activity. In addition, structure-activity relationship evaluation of LR-11 analogs suggested that its biological function was closely associated with preservation of the original amino acid sequence and balanced physicochemical properties. Overall, these findings highlight Asian seabass by-products as a valuable and sustainable source of anti-inflammatory peptides and identify LR-11 as a promising candidate for future applications in nutraceutical and therapeutic development.
Indexed as
Identifiers
42012727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.